Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announces the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leukemia, and we look forward to working with the Terns team to advance its clinical development.”
Read the full article: Merck Completes Acquisition of Terns Pharmaceuticals, Inc. //
Source: https://www.businesswire.com/news/home/20260505216715/en/Merck-Completes-Acquisition-of-Terns-Pharmaceuticals-Inc.